Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Featured trial
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early

parkinsonism
bradykinesia
dopamine
resting tremor
early parkinson's
  • 160 views
  • 28 Oct, 2022
  • 104 locations
Featured trial
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's

early parkinson's
  • 44 views
  • 17 Nov, 2022
  • 72 locations
Flexible-Dose Trial in Early Parkinson's Disease (TemPo-2)

The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.

levodopa
dopamine
bradykinesia
dopamine agonists
dopa
  • 54 views
  • 31 Oct, 2022
  • 35 locations
A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease

The purpose of this study is to measure safety and efficacy of buntanetap capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months. The double-blind treatment duration will be up to 6 months. There will be 5 in-clinic …

mini-mental state examination
  • 5 views
  • 01 Nov, 2022
  • 16 locations
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA/DDCI in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Carbidopa and benserazide are both …

  • 0 views
  • 04 Aug, 2021
  • 1 location
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease

REM Behavior Sleep Disorder (RBD) is a sleep disorder causing people to 'act out' their dreams. A high percentage of individuals with idiopathic RBD (iRBD) are known to develop conditions affecting the neurons in the brain such as Parkinson's disease (PD). Based on the increased risk to develop PD, individuals …

  • 0 views
  • 07 Oct, 2022
  • 1 location
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

REM Behavior Sleep Disorder (RBD) is a sleep disorder causing people to 'act out' their dreams. A high percentage of individuals with idiopathic RBD (iRBD) are known to develop conditions affecting the neurons in the brain such as Parkinson's disease (PD). Based on the increased risk to develop PD, individuals …

depression
metaiodobenzylguanidine
sleep disorder
dopamine transporter
dyschromatopsia
  • 64 views
  • 07 Oct, 2022
  • 1 location
A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease (NOPARK)

NOPARK is a double-blinded randomized controlled trial that studies nicotinamide supplementation in early Parkinson's disease. Parkinson's disease (PD) is a major cause of death and

malnutrition
datscan
early parkinson's
  • 44 views
  • 25 Jan, 2022
  • 2 locations
Gut Microbiota in the Progression of Alpha-synucleinopathies

The aim of this study is to correlate baseline gut microbiota features and the progression of neurodegeneration in the established cohort of patients with early Parkinson's disease.

  • 0 views
  • 02 Jun, 2022
  • 1 location
The GBA Multimodal Study in Parkinson's Disease

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and …

acetylcholine
dopamine
parkinson's disease
gba gene
positron emission tomography
  • 4 views
  • 25 Jan, 2022
  • 3 locations